Latest Targeted therapy Stories
SAN DIEGO, Jan.
Novel Diagnostic Helping Answer U.S. President's Call for Action on Precision Medicine Initiative JERUSALEM, Jan.
Second Orphan Designation for OncoSynergy's Novel Multi-Indication Platform Drug SAN FRANCISCO, Jan.
Prospective clinical studies to evaluate Trovagene's Precision Cancer Monitoring platform to determine the emergence of resistance mutations using circulating tumor DNA SAN DIEGO,
Research Presented at 2015 Gastrointestinal Cancers Symposium Highlights Clinical Utility of Caris Molecular Intelligence in Elucidating Disease Biology and Identifying Potential Treatment Options
RnRMarketResearch.com adds “Erbitux (Colorectal Cancer) – Forecast and Market Analysis to 2023” to its store.
-- Novel irreversible pan-erbB inhibitor is active against patient-derived GBM xenografts overexpressing EGFR, including the disease-driving EGFRvIII mutation MENLO PARK, Calif., Dec.
Studies Using Caris Molecular Intelligence(TM) Identify Standard as well as Novel Therapeutic Options Based on Molecular Characterization of Individual Patients' Tumors IRVING, Texas,
LONDON and NEW YORK, November 19, 2014 /PRNewswire/ -- [[CENTER] ]http://www.abmrg.com/Global-Oncology-Market---Trends-Forecast-and-Pipeline-Analysis.html